← All trials
NCT05906576
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2023
- Primary completion
- Nov 30, 2026
- Completion date
- Feb 28, 2027
- First posted
- Jun 18, 2023
- Last posted
- Jun 18, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Mabtech Pharmaceutical Co., Ltd.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.